MedTrace Logo

Role of 90K/Mac-2 BP as an Indicator of Early Response to Infliximab Therapy in IBD Patients

NCT05960162 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-07-25

No results posted yet for this study

Summary

The aim of this study is to analyze the relationship between 90K serum levels measured at baseline and after induction in IBD patient undergoing infliximab therapy, in order to clarify the role of serum 90K as an adjuvant biomarker for IBD patients in the active phase. Furthermore, the study aims to evaluate the clinical usefulness of this new biomarker in the management of IBD patients undergoing infliximab therapy.

Conditions

Interventions

DIAGNOSTIC_TEST

90K

Blood test

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-17
Primary Completion
2024-07-17
Completion
2024-07-17

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05960162 on ClinicalTrials.gov